Guardant Health Inc., a leader in precision oncology, has expanded its tumor molecular profiling offerings with the introduction of comprehensive immunohistochemistry $(IHC)$ testing for solid tumors. This addition allows oncologists to identify tumor subtypes and match cancer patients to targeted therapies more effectively. The IHC testing covers key biomarkers such as HER2, MMR, PD-L1, c-MET, ER, PR, Ki-67, CLDN18, and FOLR1. This expansion complements the Guardant360 Tissue multiomic profiling test, providing cancer care teams with more comprehensive tissue testing capabilities to make informed therapy decisions and optimize patient outcomes. The inclusion of c-MET testing is particularly significant, as it is the target of the recently FDA-approved Emrelis™ for c-MET-expressing non-squamous non-small cell lung cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.